Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with metastatic pancreatic cancer (a type of cancer that has spread beyond the pancreas), confirmed by a tissue test.
- People who are not able to receive a chemotherapy combination called FOLFIRINOX and are about to start first-line treatment with a single chemotherapy drug called gemcitabine.
- People whose stored tumour tissue sample meets certain quality requirements needed for a specific test used in this trial (confirm with trial site).
- People with a life expectancy of more than 2 months.
- People whose cancer can be measured on scans using a standard set of measurement rules called RECIST 1.1.
- People who have not previously received any treatment for their cancer after it spread (metastatic stage).
- People aged 18 years or older.
- People who do not object to taking part in the study.
- People who are members of, or covered by, a social security or health insurance scheme (this appears to be a French healthcare requirement — confirm with trial site).
Who may not be able to join:
- People for whom gemcitabine chemotherapy is medically unsuitable or unsafe.
- People whose general health and ability to carry out daily activities falls below a certain level, as measured by a standard medical scale (confirm with trial site).
- People who are in an emergency situation or are unable to indicate whether they object to taking part.
- People who are under a legal protection order, such as guardianship or a similar arrangement.
- People who are unable to attend regular medical follow-up appointments due to geographic, social, or psychological reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0491223778
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of alive GemCore+ patients treated with Gemcitabine
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.